ARTICLE | Clinical News
Cimzia certolizumab pegol: Phase IIIb data
November 15, 2010 8:00 AM UTC
The double-blind, international Phase IIIb REALISTIC trial in 1,063 patients showed that subcutaneous Cimzia met the primary endpoint of significantly improving ACR20 response rate at week 12 vs. vs. ...